The nurse suspects that a patient has polycythemia vera based on which finding in the patient's laboratory reports? Select all that apply.
One, some, or all responses may be correct.

Choice A rationale:

Methotrexate is a medication used for cancer and autoimmune diseases. It does not chelate iron and is not used to treat iron overload conditions like hemochromatosis.

Choice B rationale:

Deferoxamine is an iron chelating agent used to treat iron overload conditions like hemochromatosis. It binds to excess iron and promotes its excretion from the body, preventing complications such as organ damage.

Choice C rationale:

Ferrous gluconate is an iron supplement used to treat iron deficiency anemia. It would not be appropriate for a patient with hemochromatosis, a condition characterized by iron overload.

Choice D rationale:

Iron dextran complex is another form of intravenous iron used to treat iron deficiency anemia. It is not indicated for treating iron overload conditions like hemochromatosis.

Choice A rationale:

Hemophilia is a hereditary disorder caused by a deficiency of specific clotting factors, and it is indeed hereditary in nature. This statement is incorrect.

Choice B rationale:

Hemophilia is a bleeding disorder where the blood does not clot properly. Replacement therapy, which involves infusing clotting factor concentrates, is a standard treatment for hemophilia. This statement is correct.

Choice C rationale:

Hemophilia is an X-linked recessive genetic disorder, not dominant. Males are more commonly affected because they have only one X chromosome, and if it carries the defective gene, they will have hemophilia. Females have two X chromosomes, and if one X chromosome carries the defective gene, the other X chromosome can compensate, making them carriers but not typically affected.

Choice D rationale:

Hemophilia A is the most common form of hemophilia, not hemophilia B.